Case Study #3

Problem

Client needed to secure a Phase-3 API supplier supporting a Phase-3 clinical trial for a cardiovascular therapeutic.

The current supplier provided a $2 million dollar proposal for registration batch.

Cost was more than double the competitive bids.

Solution

Drug Discovery Alliances evaluated the clients needs and determined a CMC consultant was needed.

The Consultant evaluated a number of supplier’s capacity, regulatory history, and cost of manufacturing in order to find the best solution.

Outcome

50% savings on initial Phase 3 batch

$10,000,0000 dollars of total savings for subsequent batches supporting commercial

$800,000,000 dollars realized by client when asset was licensed to Novartis

Author
Recent Posts

Deborah Minor

CEO at Drug Discovery Alliances

Deborah has decades of business development experience marketing contract services, drug licensing and new technologies to the pharmaceutical industry. She founded Drug Discovery Alliances, Inc. in 2001 to connect pharmaceutical and biotech companies with top industry contractors who facilitate and speed projects. Deborah earned a Ph.D. in Medicinal Chemistry from University of North Carolina, Chapel Hill and has worked as an organic chemist for Rhone Poulenc. She subsequently worked for Accelyrs and MDL, marketing molecular modeling technologies and databases including Beilstein and Crossfire to the pharmaceutical industry.